What Eramol does

Eramol is a UK-headquartered, privately held pharmaceutical contract development and manufacturing organisation (CDMO) that provides formulation development, GMP manufacturing (sterile and non-sterile), clinical packaging, labelling, Qualified Person (QP) batch release, GMP/GDP storage, and global distribution for investigational and commercial medicinal products. Founded in 2013 by Qualified Persons Peter Mollison and Eric Che, the company initially operated as a virtual QP service before evolving into an integrated operational organisation with its own GMP and GDP facilities. Today Eramol operates from four sites: Gatwick (specialised secondary packaging and kitting, founded operational site since December 2017), Dublin (EU hub for importation, QP release, storage, packaging, and labelling since August 2020), Sevenoaks non-sterile (40,000 tablets/hour GMP oral solid dose capacity since August 2022), and Sevenoaks sterile Unit 8 (purpose-built, £11 million EU GMP Annex 1-compliant aseptic fill-finish and terminal sterilisation facility acquired September 2023, with construction initiated April 2024 and operational launch targeted for Q2 2026 following MHRA inspection).

The company's core technology centres on QP-designed GMP infrastructure, including isolator-based aseptic processing, Grade A/C cleanrooms, Bonfiglioli vacuum decay container closure integrity testing (≥1 μm defect detection at ≥99.7% confidence, USP <1207> compliant), and a multi-modality sterile manufacturing capability spanning small molecules, biologics, peptides, oligonucleotides, radiopharmaceuticals, ATMPs, cell and gene therapies, ADCs, RNA therapeutics, viral vectors, monoclonal antibodies, and cytotoxics. A signature differentiator is matched placebo manufacturing using bespoke colour-matching coating processes and 3D laser scanning for dimension replication, backed by an internal stability data library. Eramol operates under MHRA and HPRA Manufacturing Authorisations (including MIA(IMP), MIA, MS) and a UK Home Office controlled substances licence, with a documented record of zero critical or major GMP deficiencies across all regulatory inspections to date.

Eramol's business model is project-based B2B services revenue, with custom pricing per programme determined by scope, batch size, regulatory complexity, and service integration. Three revenue streams are evident: (1) clinical trial manufacturing services (formulation, sterile/non-sterile manufacture, packaging, QP release, storage, global distribution, professional services model); (2) commercial drug procurement (comparator sourcing across four continents, transaction-fee model); and (3) regulatory and QP services (QP batch certification, QP auditing, IMPD creation, Brexit-navigation consulting, professional services model). The go-to-market motion is direct, consultative enterprise sales with quote-based engagement and 48-hour proposal generation, supported by content marketing (industry articles, white papers, FAQs, newsletter) targeting biopharmaceutical companies, CROs, and academic research institutions across the UK, EU, and 35+ country distribution network.

Name

Eramol

Legal name

Eramol (UK) Limited

Website

https://eramol.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

UK-based CDMO providing GMP formulation development, sterile and non-sterile manufacturing, clinical packaging, QP release, storage, and global distribution services for biopharmaceutical sponsors, CROs, and academic research institutions across the UK, EU, and 35+ countries.

Ownership category

akta.pro rank

Product category

Clinical Trial Manufacturing / Pharmaceutical Contract Development and Manufacturing (CDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Packaging and Labeling Services (561910)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

akta.pro secondary industries

Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP) (HLAGAGAG), GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Parenteral & Injectable Packaging Components (Stoppers, Seals, Syringes, Cartridges) (IMALAIAE)

Keywords

• Clinical trial manufacturing
• GMP pharmaceutical services
• Aseptic fill-finish
• Clinical packaging solutions
• Pharmaceutical supply chain

Headquarters

HQ city

Sevenoaks

HQ country

United Kingdom

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Clinical Trial Manufacturing Services: End-to-end GMP manufacturing services for investigational medicinal products (IMPs) including formulation development, sterile and non-sterile manufacturing, clinical packaging, labelling, QP release, storage, and global distribution. Revenue generated through project-based contracts for pharmaceutical sponsors and CROs.
2. Commercial Drug Procurement: Comparator and commercial drug sourcing services for clinical trials, including sourcing of commercial actives, global sourcing across four continents, and supply chain management.
3. Regulatory and QP Services: Qualified Person batch certification, QP auditing, regulatory consulting, IMPD creation, and Brexit navigation services including EU & UK QP verification and importation services.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Eramol is a bespoke clinical trial manufacturing services provider offering an integrated portfolio of 11 GMP pharmaceutical services including formulation development, sterile and non-sterile manufacturing, placebo manufacturing, clinical packaging, labelling, QP release, storage and distribution, EU and UK importation, commercial drug procurement, and clinical supply chain solutions. The company operates its own GMP and GDP facilities across the UK (Sevenoaks, Gatwick) and EU (Dublin), delivering end-to-end clinical-to-commercial supply for pharmaceutical sponsors, biotechs, CROs, and research institutions.

Product overview

Eramol is a bespoke clinical trial manufacturing services provider offering a unified portfolio of integrated pharmaceutical services. The company's core offering consists of 11 interconnected service modules: Formulation Development, Sterile Manufacturing, Non-Sterile Manufacturing, Placebo Manufacturing, Clinical Packaging, Labelling Solutions, EU & UK QP Release, Clinical Storage & Distribution, EU & UK Importation, Commercial Drug Procurement, and Clinical Supply Chain Solutions. These services are designed to work together as an end-to-end offering, enabling clients to move seamlessly from early clinical development through to commercial manufacture and global distribution. Eramol operates its own GMP and GDP facilities across the UK (Sevenoaks sterile and non-sterile, Gatwick) and EU (Dublin), providing manufacturing, packaging, quality control, QP release, storage, and global distribution under one quality system.

Differentiator

Problem solved

Functional benefit

Products and services

• Formulation Development Clinical formulation development services covering placebo formulation development, analytical method development and stability studies, pre-GMP formulation, GMP transfer and scale up, and deformulation and characterisation. Offered to pharmaceutical sponsors and CROs seeking to reduce time to market for clinical programmes.
• Sterile Manufacturing EU GMP Annex 1-compliant sterile manufacturing service dedicated to Phase I and Phase II clinical trial supply, featuring isolator-based aseptic processing and terminal sterilisation for vials, cartridges, and pre-filled syringes. Maximum batch size 10 L; over 1,000 sterile vials per day throughput. Supports small molecules, biologics, peptides, oligonucleotides, radiopharmaceuticals, ATMPs, cell and gene therapies, ADCs, RNA therapeutics, viral vectors, monoclonal antibodies, and cytotoxic products.
• Non-Sterile Manufacturing GMP production of tablets, capsules, and oral liquids for Phase I–III and commercial supply, with capacity of 40,000 tablets per hour and tablet sizes from 5 mm to 25 mm. Operated at the Sevenoaks non-sterile facility (operational since August 2022).
• Placebo Manufacturing Matched placebo tablets, over-encapsulation, and liquid blinding services for clinical trials and product testing. Features bespoke colour-matching coating processes and 3D laser scanning for dimension replication supported by a stability data library; supports blinding integrity and regulatory compliance for randomised controlled trials.
• Clinical Packaging Primary and secondary packaging services for clinical trial supplies including bottling, blistering, kit assembly, and cartoning. Provided across the Sevenoaks and Gatwick facilities to support clinical and commercial packaging requirements.
• Labelling Solutions Versatile labelling solutions including just-in-time labelling, multi-lingual booklet labels, and single panel labelling, designed for flexibility and last-minute requirements in clinical trial supply.
• EU & UK QP Release Qualified Person batch certification and release services for UK and EU clinical and commercial drug products, including QP auditing, seamless transition between jurisdictions, third-country GMP declarations, and Rest of World release support. Underpinned by over 40 years of combined QP experience.
• Clinical Storage & Distribution GMP/GDP-compliant storage and distribution services with temperature-controlled options from -80°C to 15–25°C, including direct-to-patient supply, controlled substance handling, IOR and customs services, and Brexit-aligned distribution solutions for clinical and commercial products.
• EU & UK Importation Full importation services including UK verification process for EU QP supply chains, physical importation sites in Ireland and the UK, Importer of Record (IOR) and customs clearance services, and IMP importation support post-Brexit.
• Commercial Drug Procurement End-to-end comparator sourcing service including global sourcing of commercial actives, working with validated supplier networks across four continents for investigational medicinal products (IMPs), non-IMPs, and auxiliary drugs. Supports hundreds of clinical studies globally.
• Clinical Supply Chain Solutions Specialist supply chain services including supply chain assessments, temperature-controlled shipments through partner couriers, direct-to-patient deliveries, and Importer of Record management across UK, EU, North America, South America, Asia Pacific, Africa, and the Middle East.

Quantifiable outcome

• Zero critical or major GMP deficiencies across all MHRA and HPRA regulatory inspections
• +2 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Specialist Courier NetworkcoreChannel Partner/ Reseller/ DistributorPartnership with specialist couriers for global temperature-controlled shipments. Includes same day, direct, next day, and cold chain shipment options. Couriers provide local depot storage and distribution operations with temperature verification for all site shipments. Validated transportation shippers for small site and pallet shipments, as well as temperature-controlled vehicle shipments for UK and EU transportations.

Scale indicators9 records

Recent moves12 records

Expansion highlights6 records

Direct peers

• Symbiosis Pharmaceutical Services: UK-based specialist sterile fill-finish CDMO focused on clinical and small-batch commercial supply, including ATMPs and biologics. Highly comparable to Eramol on the sterile clinical manufacturing side and similar in size and specialisation.
• Sharp Clinical Services: Clinical packaging, labelling, storage, and distribution specialist serving pharma and biotech sponsors. Closely overlaps with Eramol's clinical packaging, labelling, and QP release services.
• PCI Pharma Services: Global CDMO with strong clinical trial supply, sterile fill-finish, packaging, labelling, and QP services. Comparable to Eramol in the integrated clinical services model but with much broader global capacity.
• CMAC: University of Strathclyde spin-out operating as a clinical manufacturing facility for small-batch sterile and non-sterile medicines, with a similar early-phase clinical supply focus and GMP manufacturing capabilities to Eramol.
• Almac Group: Northern Ireland-headquartered global CDMO with a large clinical trial supply and contract manufacturing business spanning formulation, sterile manufacturing, packaging, and QP release. Closest direct peer to Eramol given UK/Ireland footprint and integrated clinical services model.

Broad incumbents

• Catalent: Large global CDMO with extensive clinical and commercial manufacturing capabilities across oral, sterile, and biologic dosage forms. Competes with Eramol in early-phase clinical manufacturing but at materially larger scale and broader modality coverage.
• Thermo Fisher Scientific (Patheon): Global pharma services and CDMO business, including Patheon clinical and commercial manufacturing. Overlaps with Eramol on clinical manufacturing and QP/release services, with significantly larger capacity and global footprint.
• Recipharm: European CDMO with clinical and commercial manufacturing services, including sterile fill-finish and oral solid dose. Overlaps with Eramol on clinical manufacturing and packaging, with broader geographic reach.
• Piramal Pharma Solutions: Global CDMO offering sterile and non-sterile manufacturing, clinical supply, and integrated development services. Comparable to Eramol on clinical manufacturing and integrated services, with substantially larger scale.

Emerging players

• Berkshire Sterile Manufacturing: US-based sterile fill-finish CDMO focused on clinical and small-batch commercial supply for biologics and injectables. Comparable to Eramol's sterile manufacturing focus but with a US-centric customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/eramol

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eramol